Cargando...
ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY
INTRODUCTION: Evophosphamide is a hypoxia-activated prodrug that, when activated in hypoxic conditions, (<0.5% O2), releases the bis-alkylating agent bromo-isophosphoramide mustard (Br-IPM). Our prior phase 1 study in recurrent GBM (rGBM) with dose expansion showed preliminary activity with a 24%...
Guardado en:
| Publicado en: | Neuro Oncol |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216171/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.051 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|